Division of Cardiovascular Medicine, Lexington, Kentucky, USA.
Curr Opin Lipidol. 2011 Aug;22(4):302-7. doi: 10.1097/MOL.0b013e3283488c39.
Serum amyloid A (SAA) is a family of acute-phase proteins which are shown to correlate with cardiovascular disease, but whether this SAA contributes causally to atherosclerosis development or reflects underlying disease or risk factors remains unclear.
SAA has been detected within atherosclerotic lesions and within adipose tissue where it is hypothesized that it may play a contributory role in disease development. In the acute-phase response SAA is synthesized by the liver and transported primarily in association with HDL. However, there is a growing literature suggesting that localized synthesis of SAA within the vasculature, or adipose tissue, may play a distinct role in disease development. Furthermore, SAA can be found in association with apoB-containing lipoproteins, in which its biological activity may be different.
This review will discuss recent experimental evidence supporting a causal role of SAA with atherosclerosis.
血清淀粉样蛋白 A(SAA)是一类急性时相蛋白,与心血管疾病相关,但 SAA 是否会导致动脉粥样硬化的发生,或者它是否反映了潜在的疾病或风险因素,目前仍不清楚。
在动脉粥样硬化斑块内和脂肪组织中都检测到了 SAA,据推测它可能在疾病发展中起作用。在急性期反应中,SAA 由肝脏合成,并主要与高密度脂蛋白(HDL)结合运输。然而,越来越多的文献表明,SAA 在血管或脂肪组织中的局部合成可能在疾病发展中起独特的作用。此外,SAA 可以与载脂蛋白 B 包含的脂蛋白结合,其生物学活性可能不同。
本综述将讨论最近支持 SAA 与动脉粥样硬化之间存在因果关系的实验证据。